ABSTRACT Background. Because of its rarity, adenocarcinoma of the small intestine is frequently compared to adenocarcinoma of the colon, although the validity of this comparison is not known. Methods. Patients with small and large bowel adenocarcinoma (SBA and LBA) diagnosed between 1988 and 2007 were identified from the Surveillance, Epidemiology, and End Results registry. Age-standardized incidence and mortality rates were determined. Cancer-specific survival (CSS) stratified by stage and by number of assessed lymph nodes was calculated. Results. A total of 4518 and 261,521 patients with SBA and LBA, respectively, were identified. In comparison to LBA, patients with SBA were younger and presented with disease of higher stage and histologic grade. The agestandardized incidence rates decreased for LBA (-1.24% per year) but increased for SBA (?1.47% per year). Although age-standardized mortality rates decreased for both LBA and SBA, the decreases were more pronounced for LBA. Five-year CSS was worse for resected SBA compared with resected LBA, although this difference diminished when comparing cases having eight or more lymph nodes assessed. The relative reduction in CSS when selecting eight or more lymph nodes was much greater for duodenal as opposed to jejunal/ileal subsite of the small bowel. With nodal selection the absolute difference in CSS between LBA and SBA for stages I, II, and III was 13, 15.9, and 18.5%, respectively.
Conclusions. Adequate nodal assessment is much less common in SBA than LBA; and it appears that SBA, in particular duodenal adenocarcinoma, is understaged. Even after corrections to minimize the effect of stage migration and inadequate lymph node evaluation, SBA demonstrated distinctly worse CSS than LBA.
Adenocarcinoma of the small intestine is a rare, orphan malignancy. Although it is the second most common malignancy of the small intestine, only 2,000 to 3,000 new cases will be diagnosed in the United States in 2009. 1, 2 At present, the clinical management for patients with small bowel adenocarcinoma (SBA) is based on the management paradigms used in large bowel adenocarcinoma (LBA) (i.e., colon cancer), but the validity of such an approach is not known.
Adenocarcinomas of the small bowel are commonly perceived as having a clinical behavior similar to that of adenocarcinomas of the large bowel. In particular, both tumors share similarities in staging, prognostic factors, and metastatic site predilection. 1, [3] [4] [5] Moreover, in patients with metastatic disease, response rates to cytotoxic chemotherapy are comparable for both sites, and recent data support fluoropyrimidine and oxaliplatin as standard first-line therapy for SBA. 6 Carcinogenesis for SBA appears to occur via a similar phenotypic adenoma to carcinoma transformation as occurs in colorectal cancers. 7, 8 From a molecular perspective, a number of alterations, such as 18q loss, p53 loss, and activating mutations in kras, occur at similar rates in both SBA and LBA. [9] [10] [11] [12] [13] Surprisingly, mutations in the adenomatous polyposis coli (APC) gene differ markedly between SBA (7-13%) and LBA (60-68%). 12, [14] [15] [16] The limited rate of APC mutations in SBA correlates with the lower rate of adenomas within the small intestine. 17 This is likely part of the reason for the most dramatic difference between adenocarcinomas of the small and large intestine: the 50-fold difference in incidence between these two sites. 18, 19 On the basis of these molecular findings, it may be hypothesized that part of the difference in incidence between these two cancers may reflect a difference in adenoma initiation rather than a biological difference between these two adenocarcinomas.
We therefore sought to conduct a population based comparison of adenocarcinomas of the small and large intestine in order to explore the differences and similarities in clinical features, presentation, incidence, and mortality for these two tumor types. As clinical management for SBA rests on the comparisons to LBA, the validity of this comparison has direct clinical ramifications. Eligible patients were aged 18 to 90 years with a histologic diagnosis of SBA [duodenum (C17.0), jejunum (C17.1), ileum (C17.2), small bowel not otherwise specified (C17.9)] or LBA [cecum (C18.0), ascending colon (C18.2), hepatic flexure of colon (C18.3), transverse colon (C18.4), splenic flexure of colon (C18.6), sigmoid colon (C18.7), overlapping lesion of colon (C18.8), and colon not otherwise specified (C18.9)]. All patients had undergone cancer-directed surgery, defined as local excision or radical resection with a specimen available for pathologic review, except for stage IV patients where surgical resection was not an inclusion criteria. Exclusion criteria included: in situ disease and lack of histology, survival time \1 month, cancer reporting from a nursing home, hospice, autopsy, or death certificate, and for stage I, II, or III cases if incomplete data regarding tumor and nodal stage precluded stage assignment. The majority of exclusions, 14.4% (n = 760) of the small bowel cohort and 16.8% (n = 52,896) of the large bowel cohort, were the result of lack of information to permit staging for analysis. In particular, the major reason was absence of lymph node (LN) status in greater than 80% of both SBA and LBA cohorts. All patients were restaged according to the AJCC 7th edition and stage stratified outcomes for LBA and SBA were directly compared by this staging system. 20 
METHODS

Patients
Statistical Analysis
Survival outcomes were determined by SEER data through December 2007, and cancer-specific survival (CSS) was estimated by the Kaplan-Meier method. For CSS analyses, cases were censored if the patient was alive at follow-up or if death was from causes other than intestinal or pancreatic cancer (SEER cause of death recode 21030-50 and 21100) for patients with SBA and from causes other than intestinal cancer for patients with LBA. A total of 2,232 patients with SBA and 76,828 patients with LBA died of their disease over the study time period. For SBA the cause of death was due to SBA in 1,516 (68%), colorectal cancer in 479 (22%), and pancreatic cancer in 237 (10%). On the basis of our previous work, the eight-node cut point for adequate LN evaluation was used in this analysis. 21 Multivariate Cox regression analysis was employed to calculate the adjusted survival based on the regression model and stratified by tumor stage. Covariates adjusted in the model included clinically and demographic relevant factors such as age, sex, race, tumor stage, tumor site, and tumor grade.
Trends in incidence and mortality rate over time were determined by using the annual percentage change, which is calculated by fitting a regression line to the natural logarithm of the rates (r) using the calendar year (x) as a regressor variable: log(r) = mx ? b. Annual percentage change significance testing compared the obtained annual percentage change to an annual percentage change of 0, which represents a lack change in the rates over time. All rates were age-adjusted based on the 2000 U.S. standard population.
Statistical analyses were performed by Stata MP Software, version 10.1 (release 2009; College Station, TX). Because the study used preexisting data with no personal identifiers, it was exempt from review by our institutional review board.
RESULTS
Patient Population
A total of 4,518 cases of SBA and 261,521 cases of LBA met the inclusion criteria within the SEER registry from 1988 to 2007 (Table 1 ). The median age was 67 [interquartile range (IQR) 56-76] and 71 years (IQR 62-79), P \ 0.01, for SBA and LBA, respectively. Patients with SBA were more likely to be males (54% vs. 49%, P \ 0.01) and to be identified as of black race (16% vs. 10%, P \ 0.01) when compared to LBA. Patients with SBA were also more likely to present with stage IV disease (32% vs. 20%, P \ 0.01) and with high grade tumors (33% vs. 21%, P \ 0.01). The total number of LNs assessed among patients with SBA was positively associated with tumor size (P = 0.001). Also the total number of assessed LNs was greater among patients with LBA, although the difference decreased with advancing stage. The median total number of LNs and interquartile range for SBA in comparison to LBA by stage was 0 (0-6) versus 9 (5-15) for stage I disease, P \ 0.01; 4 (0-10) versus 12 (7-18) for stage II disease, P \ 0.01; and 8 (3-13) versus 12 (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) for stage III disease, P \ 0.01. Within SBA, the median number and IQR of the total number of assessed LNs was greatest for the ileal subsite (8, (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) as compared to jejunal (6, 2-10; P \ 0.01) and duodenal (4, 0-11; P \ 0.01) subsites.
Trends in Incidence
The age-standardized incidence rates for adenocarcinomas of the small and large intestine are shown in Fig. 1 . The annual percentage change in incidence was decreasing for LBA (-1.24% per calendar year), but increasing for SBA (?1.47% per calendar year). When stratified into early (I-II) or advanced (III-IV) stage cohorts, the increasing incidence for SBA was more pronounced for early stage disease (1.93% per year vs. 1.15% per year), and the decreasing incidence for LBA was slightly more pronounced for early stage disease (-1.29% per year vs. -1.18% per year).
Trends in Mortality
A consistent decline in age-standardized mortality rates was seen for LBA with an annual percentage change of -2.31% per year (Fig. 1c) . SBA age-standardized mortality rates appear relatively stable, with a slightly decreasing rate noted since approximately 1998 (Fig. 1d ).
Stage-Stratified Mortality
As the risk of death from cancer is strongly related to stage at presentation, CSS was calculated by the KaplanMeier method for each stage (Fig. 2a) . SBA demonstrated far worse outcomes than for LBA. As a prior analysis has identified eight or more assessed LNs to be a statistically significant stage-stratified discriminator of outcomes among patients with SBA, we compared this subset of patients to those patients with LBA. 21 When only patients with eight or more assessed LNs were analyzed, the difference in CSS between SBA and LBA reduced with LN selection resulting in a relative reduction in the difference between stage I, II and III SBA and LBA of 53, 45, and 19%, respectively (Fig. 2b) .
As the number of assessed LNs varied by small bowel subsites, we compared the subsites of the small bowel, duodenal and jejunal/ileal, with LBA ( Table 2 ). The improvement in CSS with the selection eight or more assessed LNs differed by small bowel subsite and disease stage. Interestingly, the relative reduction in cancer specific mortality with the selection of eight or more assessed LNs was greatest for stages I and II duodenal adenocarcinoma. However, after the selection of 8 assessed LNs, the CSS was similar for duodenal and jejunal/ileal subsites, and the difference in CSS when compared to LBA was similar across stage I, II, and III disease. 
DISCUSSION
This study provides new insights into the rare malignancy of small intestinal adenocarcinoma. Although improvements in survival have occurred for both adenocarcinomas of the small and large intestine, the improvements for SBA are markedly smaller than those for LBA. In contrast to LBA the incidence of SBA continued to climb over time. Stage-perstage, survival among patients with resected LBA was better than that for patients with resected SBA. A large part of this effect may be explained by stage migration because after stratification for patients with 8 LN assessed, there was a marked reduction in the adjusted difference between SBA and LBA. The effect was particularly large for stage I and II duodenal adenocarcinomas suggesting a high degree of understaging for this small bowel subsite. In cases with eight or more LNs assessed the absolute difference in CSS between LBA and SBA remained relatively stable across stages, with an overall difference of 13% for stage I, 15.9% for stage II, and 18.5% for stage III. These findings suggest that distinct differences in biology and treatment patterns may exist between these two intestinal malignancies, and strongly supports further research to understand the molecular mechanisms of adenocarcinoma of the small intestine.
Although the exact explanation for the divergence in age-standardized incidence trends for SBA and LBA cannot be determined from these data, the impact of successful screening for colorectal polyps and cancer is likely at least partly responsible. 22, 23 Aside from upper endoscopy for patients with familial adenomatous polyposis (FAP), no known screening recommendations exist for patients at risk for SBA. However, the rising incidence of SBA may in part be related to improvements in small bowel evaluation with the use of capsule endoscopy and improved methods of abdominal imaging (e.g., CT scan).
Whether a portion of the divergence in incidence trends reflects the role of differing etiologic and environmental risk factors for carcinogenesis in the small and large intestine cannot be determined in this study. However, prior studies have suggested a number of similarities regarding risk factors for both small and large intestinal adenocarcinoma. Two population based studies have demonstrated an increased risk for SBA after a diagnosis of LBA and vice versa. 24, 25 Epidemiologic studies have demonstrated associations between SBA and the use of tobacco, consumption of animal fat and alcohol, each of which are also associated with risk for LBA. [26] [27] [28] [29] In addition, the inheritable colorectal cancer syndromes of hereditary nonpolyposis colorectal cancer and FAP, as well as inflammatory bowel disease, are strong risk factors for developing adenocarcinoma in both the small and large intestine.
Improvements in mortality were seen for both SBA and LBA during the study period, although the reduction for SBA was smaller and only seen after approximately 1998. For both LBA and SBA this improvement in outcome is likely multi-factorial and may be related to changes in supportive care, surgical technique, adjuvant therapy, and systemic chemotherapy. Although limited data exist regarding benefits of adjuvant chemotherapy for SBA, a recent analysis of the National Cancer Data Base demonstrated an increasing rate of adjuvant chemotherapy use from 8% of cases in 1985 to 24% in 2005.
1 Interestingly the greater increase in incidence of stage I and II as compared to stage III and IV SBA indicates a shift toward earlier diagnosis. However, the percentage of patients diagnosed with stage I/II disease remains dramatically lower for SBA than LBA, 40% as compared to 52%, respectively. The recent incorporation of capsule endoscopy has provided an improved method of evaluating the small intestine and radiographic CT imaging technology for the evaluation of abdominal complaints has also improved. Irrespective of the reasons for the decline in mortality for this rare cancer, this finding is encouraging and represents the first demonstration of improving outcomes for this cancer.
Perhaps the most interesting observation arises from the comparison of survival outcomes of patients with SBA who underwent surgical resection with evaluation of 8 LNs to stage matched patients with LBA. For both LBA and SBA the correlation between increasing nodal assessment and improved survival has been demonstrated. 21, 30 As is seen in colorectal cancer, this association is likely the result of the combined effects of improved stage-assignment and improved oncologic clearance of micrometastatic disease as well as patient and tumor biology related factors. How these various factors impact the LN yields for SBA is not known but the same factors are likely relevant, as studies in other tumor types have noted the importance of these same factors. 31, 32 In a prior SEER registry study, assessment of eight or more LNs was identified to be the optimal cutpoint for discriminating differences in CSS. 21 We therefore utilized this cut point in the present analysis as a means to minimize the potential effects of stage migration. Thus, among patients who had eight or more LNs evaluated at the time of resection, the risk of unresected residual nodal metastasis and stage misassignment should be minimized and the survival comparisons are expected to reflect the true natural history of the disease.
The greater relative improvement in adjusted CSS for stages I (23%) and II (27.1%) than for stage III (12.8%) SBA after stratification for eight or more LNs suggests that stage migration with improved LN assessment is occurring in stage I and II disease. This finding is consistent with a prior study. 33 However, in our analysis, we found that the understaging of SBA was strongly dependent on small bowel subsite, with duodenal subsite being predominantly responsible for this effect with a relative improvement in CSS for stages I, II and III of 32.6, 48.9, and 14%, respectively. In fact, for the jejunal/ileal subsite the selection of eight or more LNs assessed, had minimal impact on stage I disease (relative improvement in CSS of 1.5%) and a similar impact across stage II and III disease (relative improvement in CSS of 10.7 and 11.6%, respectively). Interestingly, even though stage I adenocarcinomas of the jejunum and ileum had similar CSS with or without LN selection, their 5-year CSS differed from stage I LBA, 81.6% versus 93.3%, respectively.
Despite the variable reduction in CSS among the subsets analyzed with the selection of eight or more LNs, the absolute difference in CSS between LBA and SBA was similar across both subsites of the small bowel and stages of disease in cases with 8 LNs assessed ( Table 2 ). This consistent difference between LBA and SBA may suggest an underlying biological difference between small and LBA or a difference in treatment patterns between these two sites. As evidence for improved outcome with adjuvant therapy has been demonstrated for LBA but not for SBA, it is likely that more patients with LBA in this data set received adjuvant chemotherapy. However, given that chemotherapy use is stage related, the fact that our findings were consistent for all stages suggests that this was not a big limitation of our analysis.
Epidemiologic studies of cancer specific survival are reliant on the accuracy of cause of death ascertainment. Although prior studies of the SEER registry have indicated the accuracy of cause of death coding, we identified a high percentage of patients with SBA having a cause of death attributed to either colorectal or pancreatic cancer. 34, 35 This indicates the difficulty in cause assignment as a result of the rarity of SBA and suggests that the anatomic proximity and treatment similarities between these sites may lead to misassignment. However, we confirmed our analyses by multivariate relative survival methods and observed the same trends as reported by CSS (data not shown).
As with most registry-based observational studies, this analysis has both strengths and limitations. As an observational study, our analysis was not designed to prove an underlying biological relationship between SBA and LBA, but rather to provide an exploratory analysis highlighting the similarities and differences that may or may not support a comparative approach in clinical practice. SEER does not provide information regarding comorbidities, pathologic margin status, detailed surgical procedure performed, nor receipt of chemotherapy. Although 14% of our small bowel cohort was excluded because of a lack of staging information, this number was similar to our large bowel cohort (17%) and the major reason for both tumors types was lack of nodal information. As the median number of assessed LNs was greater for LBA as for SBA, a greater selection bias was placed on SBA when selecting for cases with eight or more LN. It is plausible that surgical differences would exist between SBA and LBA, as SBA is a rare cancer and the criteria for and expertise with performing an optimal cancer-directed surgery for SBA have not been well established. As the surgical approach and patient selection criteria are different for duodenal as compared to nonduodenal sites, it is likely that this difference in complexity is partially reflected in the lower rate of duodenal as opposed to nonduodenal cases with eight or more LN, 26 and 35%, respectively. In addition the inability to effectively identify and diagnose small bowel tumors preoperatively may not permit adequate preoperative planning, which may impact the nature and extent of the surgical resection. Despite these limitations, the SEER registry, which captures data from 26% of the cancer cases within the United States, represents one of the largest data sets of this rare cancer and provides valuable information beyond the single institutional retrospective studies that currently dominate the literature.
The differences in survival outcomes for patients with SBA or LBA highlight the underlying biological differences between these two cancers. However, the marked reduction in this effect after stratification for adequate LN assessment shows that the prognosis for adequately treated and evaluated SBA may not be as poor as once thought. Adequate nodal assessment is much less common in SBA than LBA, and it appears that a high degree of understaging may be occurring for stage I and II SBAs, particularly of the duodenum. Comparative analysis between a potentially related rare and common cancer, provides a novel way to gain insights into a cancer with limited available information.
